STOCK TITAN

Genmab directors sell 617 and 351 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Genmab A/S (GMAB) disclosed share sales by two members of its Board of Directors on November 12, 2026. Martin Schultz sold 617 shares and Mijke Zachariasse sold 351 shares; each transaction was reported at DKK 3,540.87. The company said the transactions were disclosed under Article 19 of Regulation No. 596/2014.

Filing Explained

The filing gives no trading-plan status for either director’s sale; they are sales with no plan disclosed here, and the filing does not establish whether either was made under a plan.

Shares sold by Martin Schultz 617 shares Member of the Board of Directors; transaction reported November 12, 2026.
Reported sale price for Martin Schultz DKK 3,540.87 Sale reported November 12, 2026.
Shares sold by Mijke Zachariasse 351 shares Member of the Board of Directors; transaction reported November 12, 2026.
Reported sale price for Mijke Zachariasse DKK 3,540.87 Sale reported November 12, 2026.
person discharging managerial responsibilities regulatory
"Details of the person discharging managerial responsibilities"
A person discharging managerial responsibilities is an individual who holds a senior role with authority to make or influence a company’s strategic or operational decisions, such as executives, board members, or other top managers. Investors care because these people often have access to confidential information and their buying or selling of company shares must be disclosed—like a referee who knows the score before the crowd, their actions can signal important, non-public insights about a company's prospects.
closely associated persons regulatory
"managerial employees and their closely associated persons"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did GMAB directors report selling?

Two Genmab A/S (GMAB) directors reported sales on November 12, 2026: Martin Schultz sold 617 shares and Mijke Zachariasse sold 351 shares, each at a reported price of DKK 3,540.87.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF NOVEMBER 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F  Form 40-F 
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.







EXHIBIT INDEX
ExhibitDescription of Exhibit
99.1
Company Announcement Dated November 12, 2026





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
GENMAB A/S
BY:/s/ Anthony Pagano
Name: Anthony Pagano
Title: Executive Vice President & Chief Financial Officer

DATE: November 12, 2026


Exhibit 99.1

genmab_logo.jpg

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement

COPENHAGEN, Denmark; November 12, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.

Please find below a statement of such trading in shares issued by Genmab A/S
1.
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Martin Schultz
2.
Reason for the notification
a)
Position/status
Member of the Board of Directors
b)
Initial notification/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Genmab A/S
b)
LEI-code
529900MTJPDPE4MHJ122
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument Identification code
Share


DK0010272202
b)
Nature of the transaction
Sale of shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 3,540.87
617
d)
Aggregated information - Aggregated volume - Price

617 shares
DKK 3,540.87
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark
Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 49
Page 1/4
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122



genmab_logo.jpg

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

e)
Date of the transaction
2026-11-12
f)
Place of the transaction
NASDAQ Copenhagen (XCSE, DCSE, MCSE)
Cboe Europe (CEUX, CEUD, BEUP)
Aquis Exchange Europe (AQEU, AQED, AQEA)
Turquoise Europe (TQEX, TQEM, TQEA)
Sigma X Europe (SGMV, SGMU)
Citadel Connect Europe (EUCC)
Liquidnet Europe (LNEQ)
Virtu Financial Ireland (VFSI)
XTX Markets (XTXE)
HRTEU Limited (HREU)
Jane Street Netherlands B.V. (JNSI)
Equiduct (EQTB)
XPOS (XPOS)
EBLX (EBLX)

1.
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mijke Zachariasse
2.
Reason for the notification
a)
Position/status
Member of the Board of Directors
b)
Initial notification/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Genmab A/S
b)
LEI-code
529900MTJPDPE4MHJ122
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument Identification code
Share


DK0010272202
b)
Nature of the transaction
Sale of shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 3,540.87
351
d)
Aggregated information - Aggregated volume - Price

351 shares
DKK 3,540.87
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark
Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 49
Page 2/4
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122



genmab_logo.jpg

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

e)
Date of the transaction
2026-11-12
f)
Place of the transaction
NASDAQ Copenhagen (XCSE, DCSE, MCSE)
Cboe Europe (CEUX, CEUD, BEUP)
Aquis Exchange Europe (AQEU, AQED, AQEA)
Turquoise Europe (TQEX, TQEM, TQEA)
Sigma X Europe (SGMV, SGMU)
Citadel Connect Europe (EUCC)
Liquidnet Europe (LNEQ)
Virtu Financial Ireland (VFSI)
XTX Markets (XTXE)
HRTEU Limited (HREU)
Jane Street Netherlands B.V. (JNSI)
Equiduct (EQTB)
XPOS (XPOS)
EBLX (EBLX)

About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
 
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com or follow us on LinkedIn, X, Facebook and Instagram.
Contact:    
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark
Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 49
Page 3/4
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122



genmab_logo.jpg

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons


Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark
Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 49
Page 4/4
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Filing Exhibits & Attachments

1 document

Keep reading